View Future GrowthBandaram Pharma Packtech 過去の業績過去 基準チェック /26Bandaram Pharma Packtechは、平均年間24.2%の収益成長を遂げていますが、 Forestry業界の収益は、年間 成長しています。収益は、平均年間3.1% 35%収益成長率で 成長しています。 Bandaram Pharma Packtechの自己資本利益率は1.4%であり、純利益率は0.7%です。主要情報24.18%収益成長率14.12%EPS成長率Forestry 業界の成長25.21%収益成長率35.02%株主資本利益率1.43%ネット・マージン0.71%前回の決算情報31 Mar 2026最近の業績更新Reported Earnings • May 31Full year 2026 earnings released: EPS: ₹0.25 (vs ₹0.83 in FY 2025)Full year 2026 results: EPS: ₹0.25 (down from ₹0.83 in FY 2025). Revenue: ₹629.4m (up 70% from FY 2025). Net income: ₹4.48m (down 55% from FY 2025). Profit margin: 0.7% (down from 2.7% in FY 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 29% per year and the company’s share price has also fallen by 29% per year.お知らせ • May 21Bandaram Pharma Packtech Limited to Report Q4, 2026 Results on May 30, 2026Bandaram Pharma Packtech Limited announced that they will report Q4, 2026 results at 12:15 PM, Indian Standard Time on May 30, 2026Reported Earnings • Feb 16Third quarter 2026 earnings released: EPS: ₹0.11 (vs ₹0.06 in 3Q 2025)Third quarter 2026 results: EPS: ₹0.11 (up from ₹0.06 in 3Q 2025). Revenue: ₹148.4m (up 61% from 3Q 2025). Net income: ₹1.92m (up 168% from 3Q 2025). Profit margin: 1.3% (up from 0.8% in 3Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has fallen by 25% per year, which means it is performing significantly worse than earnings.お知らせ • Feb 03Bandaram Pharma Packtech Limited to Report Q3, 2026 Results on Feb 13, 2026Bandaram Pharma Packtech Limited announced that they will report Q3, 2026 results on Feb 13, 2026Reported Earnings • Nov 15Second quarter 2026 earnings releasedSecond quarter 2026 results: EPS: ₹0.03. Revenue: ₹137.3m (up 93% from 2Q 2025). Net income: ₹331.0k (down 95% from 2Q 2025). Profit margin: 0.2% (down from 9.5% in 2Q 2025). The decrease in margin was driven by higher expenses.お知らせ • Nov 08Bandaram Pharma Packtech Limited to Report Q3, 2026 Results on Nov 13, 2025Bandaram Pharma Packtech Limited announced that they will report Q3, 2026 results at 12:15 PM, Indian Standard Time on Nov 13, 2025すべての更新を表示Recent updatesReported Earnings • May 31Full year 2026 earnings released: EPS: ₹0.25 (vs ₹0.83 in FY 2025)Full year 2026 results: EPS: ₹0.25 (down from ₹0.83 in FY 2025). Revenue: ₹629.4m (up 70% from FY 2025). Net income: ₹4.48m (down 55% from FY 2025). Profit margin: 0.7% (down from 2.7% in FY 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 29% per year and the company’s share price has also fallen by 29% per year.New Risk • May 27New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 50% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.1x net interest cover). Shareholders have been substantially diluted in the past year (50% increase in shares outstanding). Market cap is less than US$10m (₹496.4m market cap, or US$5.18m). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (9.3% average weekly change). Revenue is less than US$5m (₹458m revenue, or US$4.8m).お知らせ • May 21Bandaram Pharma Packtech Limited to Report Q4, 2026 Results on May 30, 2026Bandaram Pharma Packtech Limited announced that they will report Q4, 2026 results at 12:15 PM, Indian Standard Time on May 30, 2026New Risk • May 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.1x net interest cover). Market cap is less than US$10m (₹370.0m market cap, or US$3.87m). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.6% average weekly change). Revenue is less than US$5m (₹458m revenue, or US$4.8m).Valuation Update With 7 Day Price Move • May 11Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹28.65, the stock trades at a trailing P/E ratio of 38x. Average trailing P/E is 23x in the Forestry industry in India. Total returns to shareholders of 8.5% over the past three years.Valuation Update With 7 Day Price Move • Apr 08Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹27.15, the stock trades at a trailing P/E ratio of 36x. Average trailing P/E is 26x in the Forestry industry in India. Total returns to shareholders of 7.9% over the past three years.Reported Earnings • Feb 16Third quarter 2026 earnings released: EPS: ₹0.11 (vs ₹0.06 in 3Q 2025)Third quarter 2026 results: EPS: ₹0.11 (up from ₹0.06 in 3Q 2025). Revenue: ₹148.4m (up 61% from 3Q 2025). Net income: ₹1.92m (up 168% from 3Q 2025). Profit margin: 1.3% (up from 0.8% in 3Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has fallen by 25% per year, which means it is performing significantly worse than earnings.お知らせ • Feb 03Bandaram Pharma Packtech Limited to Report Q3, 2026 Results on Feb 13, 2026Bandaram Pharma Packtech Limited announced that they will report Q3, 2026 results on Feb 13, 2026Valuation Update With 7 Day Price Move • Jan 05Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹31.39, the stock trades at a trailing P/E ratio of 64x. Average trailing P/E is 38x in the Forestry industry in India. Total returns to shareholders of 31% over the past three years.Valuation Update With 7 Day Price Move • Dec 18Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₹26.53, the stock trades at a trailing P/E ratio of 54.1x. Average trailing P/E is 38x in the Forestry industry in India. Total returns to shareholders of 11% over the past three years.New Risk • Nov 27New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.7x net interest cover). Share price has been highly volatile over the past 3 months (9.9% average weekly change). Market cap is less than US$10m (₹396.0m market cap, or US$4.43m). Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (1.5% net profit margin). Revenue is less than US$5m (₹403m revenue, or US$4.5m).Valuation Update With 7 Day Price Move • Nov 27Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹33.00, the stock trades at a trailing P/E ratio of 67.3x. Average trailing P/E is 29x in the Forestry industry in India. Total returns to shareholders of 171% over the past three years.Reported Earnings • Nov 15Second quarter 2026 earnings releasedSecond quarter 2026 results: EPS: ₹0.03. Revenue: ₹137.3m (up 93% from 2Q 2025). Net income: ₹331.0k (down 95% from 2Q 2025). Profit margin: 0.2% (down from 9.5% in 2Q 2025). The decrease in margin was driven by higher expenses.Valuation Update With 7 Day Price Move • Nov 10Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹27.49, the stock trades at a trailing P/E ratio of 39.3x. Average trailing P/E is 35x in the Forestry industry in India. Total loss to shareholders of 39% over the past year.お知らせ • Nov 08Bandaram Pharma Packtech Limited to Report Q3, 2026 Results on Nov 13, 2025Bandaram Pharma Packtech Limited announced that they will report Q3, 2026 results at 12:15 PM, Indian Standard Time on Nov 13, 2025Board Change • Sep 11High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Non-Executive Director Mounika Pammi was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Declared Dividend • Sep 08Dividend of ₹0.10 announcedDividend of ₹0.10 is the same as last year. Ex-date: 22nd September 2025 Payment date: 28th October 2025 Dividend yield will be 0.3%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is covered by earnings (12% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has not increased over the past 2 years but payments have been stable during that time. Earnings per share has grown by 37% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.お知らせ • Sep 05Bandaram Pharma Packtech Limited, Annual General Meeting, Sep 29, 2025Bandaram Pharma Packtech Limited, Annual General Meeting, Sep 29, 2025, at 11:00 Indian Standard Time.Reported Earnings • Aug 15First quarter 2026 earnings released: EPS: ₹0.01 (vs ₹0.15 in 1Q 2025)First quarter 2026 results: EPS: ₹0.01 (down from ₹0.15 in 1Q 2025). Revenue: ₹81.0m (down 29% from 1Q 2025). Net income: ₹247.0k (down 86% from 1Q 2025). Profit margin: 0.3% (down from 1.6% in 1Q 2025). The decrease in margin was driven by lower revenue.お知らせ • Aug 09Bandaram Pharma Packtech Limited to Report Q1, 2026 Results on Aug 14, 2025Bandaram Pharma Packtech Limited announced that they will report Q1, 2026 results on Aug 14, 2025お知らせ • Jul 21Bandaram Pharma Packtech Limited Appoints Mounika Pammi as Independent DirectorBandaram Pharma Packtech Limited at its EGM held on July 21, 2025 announced the appointment of Mrs. Mounika Pammi (Din: 11111376) as an independent director of the company.お知らせ • Jun 20Bandaram Pharma Packtech Limited Approves the Resignation of Prateek Vijayvargiya as Independent Director, Effective from June 20, 2025Bandaram Pharma Packtech Limited at its board meeting held on June 20, 2025, approved the resignation of Mr. Prateek Vijayvargiya, Independent Director of the Company effective from June 20, 2025, due to his professional commitments. He has confirmed that there are no other material reasons for his resignation other than that mentioned in his resignation letter.Reported Earnings • Jun 02Full year 2025 earnings released: EPS: ₹0.83 (vs ₹0.79 in FY 2024)Full year 2025 results: EPS: ₹0.83 (up from ₹0.79 in FY 2024). Revenue: ₹370.6m (up 8.7% from FY 2024). Net income: ₹9.94m (up 4.9% from FY 2024). Profit margin: 2.7% (down from 2.8% in FY 2024). The decrease in margin was driven by higher expenses.New Risk • May 27New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. The company is paying a dividend despite having no free cash flows. Dividend yield: 0.3% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (10% average weekly change). Market cap is less than US$10m (₹464.4m market cap, or US$5.44m). Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (2.0% net profit margin). Revenue is less than US$5m (₹421m revenue, or US$4.9m).Valuation Update With 7 Day Price Move • Apr 11Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹37.24, the stock trades at a trailing P/E ratio of 52.5x. Average trailing P/E is 22x in the Forestry industry in India. Total returns to shareholders of 12% over the past year.Reported Earnings • Feb 19Third quarter 2025 earnings released: ₹0.01 loss per share (vs ₹0.46 profit in 3Q 2024)Third quarter 2025 results: ₹0.01 loss per share (down from ₹0.46 profit in 3Q 2024). Revenue: ₹100.0m (up 2.1% from 3Q 2024). Net loss: ₹134.0k (down 102% from profit in 3Q 2024).New Risk • Feb 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). High level of non-cash earnings (27% accrual ratio). Market cap is less than US$10m (₹529.2m market cap, or US$6.09m). Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Revenue is less than US$5m (₹356m revenue, or US$4.1m).Valuation Update With 7 Day Price Move • Nov 28Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹50.38, the stock trades at a trailing P/E ratio of 37.7x. Average trailing P/E is 27x in the Forestry industry in India. Total returns to shareholders of 65% over the past year.Valuation Update With 7 Day Price Move • Oct 10Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹49.01, the stock trades at a trailing P/E ratio of 54.9x. Average trailing P/E is 33x in the Forestry industry in India. Total returns to shareholders of 68% over the past year.お知らせ • Sep 13Bandaram Pharma Packtech Limited, Annual General Meeting, Sep 27, 2024Bandaram Pharma Packtech Limited, Annual General Meeting, Sep 27, 2024, at 11:00 Indian Standard Time.Valuation Update With 7 Day Price Move • Sep 12Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹37.96, the stock trades at a trailing P/E ratio of 42.5x. Average trailing P/E is 34x in the Forestry industry in India. Total returns to shareholders of 37% over the past year.Declared Dividend • Sep 07Dividend of ₹0.10 announcedDividend of ₹0.10 is the same as last year. Ex-date: 20th September 2024 Payment date: 27th October 2024 Dividend yield will be 0.2%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is covered by earnings (12% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years. Earnings per share has grown by 56% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.お知らせ • Sep 05+ 2 more updatesBandaram Pharma Packtech Limited to Report Q2, 2025 Results on Nov 14, 2024Bandaram Pharma Packtech Limited announced that they will report Q2, 2025 results on Nov 14, 2024お知らせ • Sep 04Bandaram Pharma Packtech Limited Proposes Final Dividend for the Financial Year 2023-24Bandaram Pharma Packtech Limited announced that the Board of Directors at its meeting held on September 04, 2024 considered to pay Dividend of INR 0.10 per share to the shareholders, subject to approval of shareholders for the Financial Year 2023-24.Valuation Update With 7 Day Price Move • Aug 27Investor sentiment improves as stock rises 40%After last week's 40% share price gain to ₹42.44, the stock trades at a trailing P/E ratio of 47.5x. Average trailing P/E is 34x in the Forestry industry in India. Total returns to shareholders of 53% over the past year.Reported Earnings • Aug 17First quarter 2025 earnings releasedFirst quarter 2025 results: EPS: ₹0.15. Revenue: ₹113.7m (up 94% from 1Q 2024). Net income: ₹1.78m (up 139% from 1Q 2024). Profit margin: 1.6% (up from 1.3% in 1Q 2024). The increase in margin was driven by higher revenue.お知らせ • Aug 07Bandaram Pharma Packtech Limited to Report Q1, 2025 Results on Aug 13, 2024Bandaram Pharma Packtech Limited announced that they will report Q1, 2025 results on Aug 13, 2024お知らせ • Jul 12Bandaram Pharma Packtech Limited Announces of Demise Bhandaram Muniratnam Reddy as Promoter/ Chairman & Non-Executive DirectorBandaram Pharma Packtech Limited announced sudden and untimely demise of Mr. Bhandaram Muniratnam Reddy (DIN: 09487708), Promoter/Chairman & Non-Executive Director of the Company on late hours of July 11, 2024. As an interim arrangement, the Management Team & Board of Directors shall continue the operations of the Company seamlessly.Reported Earnings • Jun 04Full year 2024 earnings released: EPS: ₹0.82 (vs ₹0.86 in FY 2023)Full year 2024 results: EPS: ₹0.82. Revenue: ₹341.1m (up 82% from FY 2023). Net income: ₹9.68m (up 276% from FY 2023). Profit margin: 2.8% (up from 1.4% in FY 2023). The increase in margin was driven by higher revenue.お知らせ • May 17Bandaram Pharma Packtech Limited to Report Q4, 2024 Results on May 29, 2024Bandaram Pharma Packtech Limited announced that they will report Q4, 2024 results on May 29, 2024Valuation Update With 7 Day Price Move • Apr 01Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₹35.21, the stock trades at a trailing P/E ratio of 44.7x. Average trailing P/E is 17x in the Forestry industry in India.Valuation Update With 7 Day Price Move • Mar 14Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹35.66, the stock trades at a trailing P/E ratio of 45.3x. Average trailing P/E is 17x in the Forestry industry in India. Total returns to shareholders of 41% over the past year.Board Change • Jan 29High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. Non-Executive Chairman Bhandaram Reddy is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Board Change • Jan 01High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. Non-Executive Chairman Bhandaram Reddy is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Oct 29Bandaram Pharma Packtech Limited to Report Q2, 2024 Results on Nov 14, 2023Bandaram Pharma Packtech Limited announced that they will report Q2, 2024 results on Nov 14, 2023お知らせ • Oct 18Bandaram Pharma Packtech Limited Approves Appointment of Priyanka Agarwal as an Additional Director (Independent Category)Bandaram Pharma Packtech Limited announced that at its board meeting held on October 17, 2023, approved the appointment of Ms. Priyanka Agarwal as an additional director (Independent category) of the company with effect from October 17, 2023. She is a Commerce Graduate and also completed executive course of ICSI.お知らせ • Sep 03Bandaram Pharma Packtech Limited, Annual General Meeting, Sep 27, 2023Bandaram Pharma Packtech Limited, Annual General Meeting, Sep 27, 2023.お知らせ • Sep 02Bandaram Pharma Packtech Limited Approves Management ChangesBandaram Pharma Packtech Limited at its Board meeting held on September 01, 2023 approved Appointment of Ms. Neha Kankariya as Company Secretary and Compliance Officer of theCompany with effect from, September 01, 2023. Ms. Neha Kankariya is a qualified Company Secretary having experience of more than 5 years in Listed Companies and having soundexposure in secretarial and legal matters. Resignation of Ms. Aakanksha as an Independent Director of the Company with effect from, September 01, 2023. Appointment of Mr. Suman Mallu as an Additional Director of the Company with effect from, September 01, 2023 in Independent category. Mr. Suman Mallu is a senior architect in Bosch Limited an automotive Industry. He is having a rich experience of more than 14 years in this field.お知らせ • Sep 01Bandaram Pharma Packtech Limited Announces Resignation of Harish Sharma as Company Secretary and Compliance OfficerBandaram Pharma Packtech Limited announced that Mr. Harish Sharma has resigned from the post of Company Secretary and Compliance officer due to his personal reasons with effect from August 31, 2023 (close of Business hours).お知らせ • Aug 05Bandaram Pharma Packtech Limited to Report Q1, 2024 Results on Aug 11, 2023Bandaram Pharma Packtech Limited announced that they will report Q1, 2024 results on Aug 11, 2023New Risk • Aug 04New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 300% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.8x net interest cover). Shares are highly illiquid. High level of non-cash earnings (41% accrual ratio). Shareholders have been substantially diluted in the past year (300% increase in shares outstanding). Market cap is less than US$10m (₹335.6m market cap, or US$4.05m). Minor Risks Paying a dividend despite having no free cash flows. Revenue is less than US$5m (₹189m revenue, or US$2.3m).Board Change • Jul 24Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 7 new directors. No experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Non-Executive Chairman Bhandaram Reddy is the most experienced director on the board, commencing their role in 2022. Additional Independent Director Aakanksha . was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Board Change • Jul 03Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 7 new directors. No experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Non-Executive Chairman Bhandaram Reddy is the most experienced director on the board, commencing their role in 2022. Additional Independent Director Aakanksha . was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.お知らせ • May 31Bandaram Pharma Packtech Limited Recommends DividendBandaram Pharma Packtech Limited recommended a dividend of INR 0.10 (10 paisa) per share subject to approval of members at the upcoming Annual General Meeting.お知らせ • May 26Bandaram Pharma Packtech Limited to Report Q4, 2023 Results on May 30, 2023Bandaram Pharma Packtech Limited announced that they will report Q4, 2023 results on May 30, 2023Board Change • May 08Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 7 new directors. No experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Non-Executive Chairman Bhandaram Reddy is the most experienced director on the board, commencing their role in 2022. Additional Independent Director Aakanksha . was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Board Change • Apr 10Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 7 new directors. No experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Non-Executive Chairman Bhandaram Reddy is the most experienced director on the board, commencing their role in 2022. Additional Independent Director Aakanksha . was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Board Change • Feb 27Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Additional Independent Director Aakanksha . was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Feb 08Bandaram Pharma Packtech Limited Announces Executive ChangesBandaram Pharma Packtech Limited announces Change in designation of Mr. B. Muniratnam Reddy from Managing Director to Non-Executive Chairman of the Company. Appointment of Mr. B. Deepak Reddy as Additional director and Managing Director (Executive Category) of the Company. Appointment of Ms. Aakanksha as additional director (Independent Category) of the Company.お知らせ • Jan 25Bandaram Pharma Packtech Limited to Report Q3, 2023 Results on Feb 01, 2023Bandaram Pharma Packtech Limited announced that they will report Q3, 2023 results on Feb 01, 2023Board Change • Nov 22Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Venkata Rajaram Chittuluru was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.収支内訳Bandaram Pharma Packtech の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史BSE:524602 収益、費用、利益 ( )INR Millions日付収益収益G+A経費研究開発費31 Mar 26629439031 Dec 25458931030 Sep 25403632030 Jun 25337829031 Mar 253701034031 Dec 24421735030 Sep 243561634030 Jun 243961127031 Mar 24341930031 Dec 23305918030 Sep 23261814030 Jun 2323059031 Mar 2318738031 Mar 22000031 Mar 21000031 Dec 180-117031 Mar 180-127031 Mar 170-117031 Mar 160000質の高い収益: 524602は 高品質の収益 を持っています。利益率の向上: 524602の現在の純利益率 (0.7%)は、昨年(2.7%)よりも低くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: 524602過去 5 年間で収益を上げており、収益は年間24.2%増加しています。成長の加速: 524602は過去 1 年間の収益成長がマイナスであったため、5 年間の平均と比較することはできません。収益対業界: 524602は過去 1 年間で収益成長率がマイナス ( -54.9% ) となったため、 Forestry業界平均 ( -12% ) と比較することが困難です。株主資本利益率高いROE: 524602の 自己資本利益率 ( 1.4% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YMaterials 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/19 14:51終値2026/06/19 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Bandaram Pharma Packtech Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • May 31Full year 2026 earnings released: EPS: ₹0.25 (vs ₹0.83 in FY 2025)Full year 2026 results: EPS: ₹0.25 (down from ₹0.83 in FY 2025). Revenue: ₹629.4m (up 70% from FY 2025). Net income: ₹4.48m (down 55% from FY 2025). Profit margin: 0.7% (down from 2.7% in FY 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 29% per year and the company’s share price has also fallen by 29% per year.
お知らせ • May 21Bandaram Pharma Packtech Limited to Report Q4, 2026 Results on May 30, 2026Bandaram Pharma Packtech Limited announced that they will report Q4, 2026 results at 12:15 PM, Indian Standard Time on May 30, 2026
Reported Earnings • Feb 16Third quarter 2026 earnings released: EPS: ₹0.11 (vs ₹0.06 in 3Q 2025)Third quarter 2026 results: EPS: ₹0.11 (up from ₹0.06 in 3Q 2025). Revenue: ₹148.4m (up 61% from 3Q 2025). Net income: ₹1.92m (up 168% from 3Q 2025). Profit margin: 1.3% (up from 0.8% in 3Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has fallen by 25% per year, which means it is performing significantly worse than earnings.
お知らせ • Feb 03Bandaram Pharma Packtech Limited to Report Q3, 2026 Results on Feb 13, 2026Bandaram Pharma Packtech Limited announced that they will report Q3, 2026 results on Feb 13, 2026
Reported Earnings • Nov 15Second quarter 2026 earnings releasedSecond quarter 2026 results: EPS: ₹0.03. Revenue: ₹137.3m (up 93% from 2Q 2025). Net income: ₹331.0k (down 95% from 2Q 2025). Profit margin: 0.2% (down from 9.5% in 2Q 2025). The decrease in margin was driven by higher expenses.
お知らせ • Nov 08Bandaram Pharma Packtech Limited to Report Q3, 2026 Results on Nov 13, 2025Bandaram Pharma Packtech Limited announced that they will report Q3, 2026 results at 12:15 PM, Indian Standard Time on Nov 13, 2025
Reported Earnings • May 31Full year 2026 earnings released: EPS: ₹0.25 (vs ₹0.83 in FY 2025)Full year 2026 results: EPS: ₹0.25 (down from ₹0.83 in FY 2025). Revenue: ₹629.4m (up 70% from FY 2025). Net income: ₹4.48m (down 55% from FY 2025). Profit margin: 0.7% (down from 2.7% in FY 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 29% per year and the company’s share price has also fallen by 29% per year.
New Risk • May 27New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 50% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.1x net interest cover). Shareholders have been substantially diluted in the past year (50% increase in shares outstanding). Market cap is less than US$10m (₹496.4m market cap, or US$5.18m). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (9.3% average weekly change). Revenue is less than US$5m (₹458m revenue, or US$4.8m).
お知らせ • May 21Bandaram Pharma Packtech Limited to Report Q4, 2026 Results on May 30, 2026Bandaram Pharma Packtech Limited announced that they will report Q4, 2026 results at 12:15 PM, Indian Standard Time on May 30, 2026
New Risk • May 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.1x net interest cover). Market cap is less than US$10m (₹370.0m market cap, or US$3.87m). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.6% average weekly change). Revenue is less than US$5m (₹458m revenue, or US$4.8m).
Valuation Update With 7 Day Price Move • May 11Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹28.65, the stock trades at a trailing P/E ratio of 38x. Average trailing P/E is 23x in the Forestry industry in India. Total returns to shareholders of 8.5% over the past three years.
Valuation Update With 7 Day Price Move • Apr 08Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹27.15, the stock trades at a trailing P/E ratio of 36x. Average trailing P/E is 26x in the Forestry industry in India. Total returns to shareholders of 7.9% over the past three years.
Reported Earnings • Feb 16Third quarter 2026 earnings released: EPS: ₹0.11 (vs ₹0.06 in 3Q 2025)Third quarter 2026 results: EPS: ₹0.11 (up from ₹0.06 in 3Q 2025). Revenue: ₹148.4m (up 61% from 3Q 2025). Net income: ₹1.92m (up 168% from 3Q 2025). Profit margin: 1.3% (up from 0.8% in 3Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has fallen by 25% per year, which means it is performing significantly worse than earnings.
お知らせ • Feb 03Bandaram Pharma Packtech Limited to Report Q3, 2026 Results on Feb 13, 2026Bandaram Pharma Packtech Limited announced that they will report Q3, 2026 results on Feb 13, 2026
Valuation Update With 7 Day Price Move • Jan 05Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹31.39, the stock trades at a trailing P/E ratio of 64x. Average trailing P/E is 38x in the Forestry industry in India. Total returns to shareholders of 31% over the past three years.
Valuation Update With 7 Day Price Move • Dec 18Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₹26.53, the stock trades at a trailing P/E ratio of 54.1x. Average trailing P/E is 38x in the Forestry industry in India. Total returns to shareholders of 11% over the past three years.
New Risk • Nov 27New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.7x net interest cover). Share price has been highly volatile over the past 3 months (9.9% average weekly change). Market cap is less than US$10m (₹396.0m market cap, or US$4.43m). Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (1.5% net profit margin). Revenue is less than US$5m (₹403m revenue, or US$4.5m).
Valuation Update With 7 Day Price Move • Nov 27Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹33.00, the stock trades at a trailing P/E ratio of 67.3x. Average trailing P/E is 29x in the Forestry industry in India. Total returns to shareholders of 171% over the past three years.
Reported Earnings • Nov 15Second quarter 2026 earnings releasedSecond quarter 2026 results: EPS: ₹0.03. Revenue: ₹137.3m (up 93% from 2Q 2025). Net income: ₹331.0k (down 95% from 2Q 2025). Profit margin: 0.2% (down from 9.5% in 2Q 2025). The decrease in margin was driven by higher expenses.
Valuation Update With 7 Day Price Move • Nov 10Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹27.49, the stock trades at a trailing P/E ratio of 39.3x. Average trailing P/E is 35x in the Forestry industry in India. Total loss to shareholders of 39% over the past year.
お知らせ • Nov 08Bandaram Pharma Packtech Limited to Report Q3, 2026 Results on Nov 13, 2025Bandaram Pharma Packtech Limited announced that they will report Q3, 2026 results at 12:15 PM, Indian Standard Time on Nov 13, 2025
Board Change • Sep 11High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Non-Executive Director Mounika Pammi was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Declared Dividend • Sep 08Dividend of ₹0.10 announcedDividend of ₹0.10 is the same as last year. Ex-date: 22nd September 2025 Payment date: 28th October 2025 Dividend yield will be 0.3%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is covered by earnings (12% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has not increased over the past 2 years but payments have been stable during that time. Earnings per share has grown by 37% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
お知らせ • Sep 05Bandaram Pharma Packtech Limited, Annual General Meeting, Sep 29, 2025Bandaram Pharma Packtech Limited, Annual General Meeting, Sep 29, 2025, at 11:00 Indian Standard Time.
Reported Earnings • Aug 15First quarter 2026 earnings released: EPS: ₹0.01 (vs ₹0.15 in 1Q 2025)First quarter 2026 results: EPS: ₹0.01 (down from ₹0.15 in 1Q 2025). Revenue: ₹81.0m (down 29% from 1Q 2025). Net income: ₹247.0k (down 86% from 1Q 2025). Profit margin: 0.3% (down from 1.6% in 1Q 2025). The decrease in margin was driven by lower revenue.
お知らせ • Aug 09Bandaram Pharma Packtech Limited to Report Q1, 2026 Results on Aug 14, 2025Bandaram Pharma Packtech Limited announced that they will report Q1, 2026 results on Aug 14, 2025
お知らせ • Jul 21Bandaram Pharma Packtech Limited Appoints Mounika Pammi as Independent DirectorBandaram Pharma Packtech Limited at its EGM held on July 21, 2025 announced the appointment of Mrs. Mounika Pammi (Din: 11111376) as an independent director of the company.
お知らせ • Jun 20Bandaram Pharma Packtech Limited Approves the Resignation of Prateek Vijayvargiya as Independent Director, Effective from June 20, 2025Bandaram Pharma Packtech Limited at its board meeting held on June 20, 2025, approved the resignation of Mr. Prateek Vijayvargiya, Independent Director of the Company effective from June 20, 2025, due to his professional commitments. He has confirmed that there are no other material reasons for his resignation other than that mentioned in his resignation letter.
Reported Earnings • Jun 02Full year 2025 earnings released: EPS: ₹0.83 (vs ₹0.79 in FY 2024)Full year 2025 results: EPS: ₹0.83 (up from ₹0.79 in FY 2024). Revenue: ₹370.6m (up 8.7% from FY 2024). Net income: ₹9.94m (up 4.9% from FY 2024). Profit margin: 2.7% (down from 2.8% in FY 2024). The decrease in margin was driven by higher expenses.
New Risk • May 27New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. The company is paying a dividend despite having no free cash flows. Dividend yield: 0.3% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (10% average weekly change). Market cap is less than US$10m (₹464.4m market cap, or US$5.44m). Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (2.0% net profit margin). Revenue is less than US$5m (₹421m revenue, or US$4.9m).
Valuation Update With 7 Day Price Move • Apr 11Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹37.24, the stock trades at a trailing P/E ratio of 52.5x. Average trailing P/E is 22x in the Forestry industry in India. Total returns to shareholders of 12% over the past year.
Reported Earnings • Feb 19Third quarter 2025 earnings released: ₹0.01 loss per share (vs ₹0.46 profit in 3Q 2024)Third quarter 2025 results: ₹0.01 loss per share (down from ₹0.46 profit in 3Q 2024). Revenue: ₹100.0m (up 2.1% from 3Q 2024). Net loss: ₹134.0k (down 102% from profit in 3Q 2024).
New Risk • Feb 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). High level of non-cash earnings (27% accrual ratio). Market cap is less than US$10m (₹529.2m market cap, or US$6.09m). Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Revenue is less than US$5m (₹356m revenue, or US$4.1m).
Valuation Update With 7 Day Price Move • Nov 28Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹50.38, the stock trades at a trailing P/E ratio of 37.7x. Average trailing P/E is 27x in the Forestry industry in India. Total returns to shareholders of 65% over the past year.
Valuation Update With 7 Day Price Move • Oct 10Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹49.01, the stock trades at a trailing P/E ratio of 54.9x. Average trailing P/E is 33x in the Forestry industry in India. Total returns to shareholders of 68% over the past year.
お知らせ • Sep 13Bandaram Pharma Packtech Limited, Annual General Meeting, Sep 27, 2024Bandaram Pharma Packtech Limited, Annual General Meeting, Sep 27, 2024, at 11:00 Indian Standard Time.
Valuation Update With 7 Day Price Move • Sep 12Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹37.96, the stock trades at a trailing P/E ratio of 42.5x. Average trailing P/E is 34x in the Forestry industry in India. Total returns to shareholders of 37% over the past year.
Declared Dividend • Sep 07Dividend of ₹0.10 announcedDividend of ₹0.10 is the same as last year. Ex-date: 20th September 2024 Payment date: 27th October 2024 Dividend yield will be 0.2%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is covered by earnings (12% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years. Earnings per share has grown by 56% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
お知らせ • Sep 05+ 2 more updatesBandaram Pharma Packtech Limited to Report Q2, 2025 Results on Nov 14, 2024Bandaram Pharma Packtech Limited announced that they will report Q2, 2025 results on Nov 14, 2024
お知らせ • Sep 04Bandaram Pharma Packtech Limited Proposes Final Dividend for the Financial Year 2023-24Bandaram Pharma Packtech Limited announced that the Board of Directors at its meeting held on September 04, 2024 considered to pay Dividend of INR 0.10 per share to the shareholders, subject to approval of shareholders for the Financial Year 2023-24.
Valuation Update With 7 Day Price Move • Aug 27Investor sentiment improves as stock rises 40%After last week's 40% share price gain to ₹42.44, the stock trades at a trailing P/E ratio of 47.5x. Average trailing P/E is 34x in the Forestry industry in India. Total returns to shareholders of 53% over the past year.
Reported Earnings • Aug 17First quarter 2025 earnings releasedFirst quarter 2025 results: EPS: ₹0.15. Revenue: ₹113.7m (up 94% from 1Q 2024). Net income: ₹1.78m (up 139% from 1Q 2024). Profit margin: 1.6% (up from 1.3% in 1Q 2024). The increase in margin was driven by higher revenue.
お知らせ • Aug 07Bandaram Pharma Packtech Limited to Report Q1, 2025 Results on Aug 13, 2024Bandaram Pharma Packtech Limited announced that they will report Q1, 2025 results on Aug 13, 2024
お知らせ • Jul 12Bandaram Pharma Packtech Limited Announces of Demise Bhandaram Muniratnam Reddy as Promoter/ Chairman & Non-Executive DirectorBandaram Pharma Packtech Limited announced sudden and untimely demise of Mr. Bhandaram Muniratnam Reddy (DIN: 09487708), Promoter/Chairman & Non-Executive Director of the Company on late hours of July 11, 2024. As an interim arrangement, the Management Team & Board of Directors shall continue the operations of the Company seamlessly.
Reported Earnings • Jun 04Full year 2024 earnings released: EPS: ₹0.82 (vs ₹0.86 in FY 2023)Full year 2024 results: EPS: ₹0.82. Revenue: ₹341.1m (up 82% from FY 2023). Net income: ₹9.68m (up 276% from FY 2023). Profit margin: 2.8% (up from 1.4% in FY 2023). The increase in margin was driven by higher revenue.
お知らせ • May 17Bandaram Pharma Packtech Limited to Report Q4, 2024 Results on May 29, 2024Bandaram Pharma Packtech Limited announced that they will report Q4, 2024 results on May 29, 2024
Valuation Update With 7 Day Price Move • Apr 01Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₹35.21, the stock trades at a trailing P/E ratio of 44.7x. Average trailing P/E is 17x in the Forestry industry in India.
Valuation Update With 7 Day Price Move • Mar 14Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹35.66, the stock trades at a trailing P/E ratio of 45.3x. Average trailing P/E is 17x in the Forestry industry in India. Total returns to shareholders of 41% over the past year.
Board Change • Jan 29High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. Non-Executive Chairman Bhandaram Reddy is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Board Change • Jan 01High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. Non-Executive Chairman Bhandaram Reddy is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Oct 29Bandaram Pharma Packtech Limited to Report Q2, 2024 Results on Nov 14, 2023Bandaram Pharma Packtech Limited announced that they will report Q2, 2024 results on Nov 14, 2023
お知らせ • Oct 18Bandaram Pharma Packtech Limited Approves Appointment of Priyanka Agarwal as an Additional Director (Independent Category)Bandaram Pharma Packtech Limited announced that at its board meeting held on October 17, 2023, approved the appointment of Ms. Priyanka Agarwal as an additional director (Independent category) of the company with effect from October 17, 2023. She is a Commerce Graduate and also completed executive course of ICSI.
お知らせ • Sep 03Bandaram Pharma Packtech Limited, Annual General Meeting, Sep 27, 2023Bandaram Pharma Packtech Limited, Annual General Meeting, Sep 27, 2023.
お知らせ • Sep 02Bandaram Pharma Packtech Limited Approves Management ChangesBandaram Pharma Packtech Limited at its Board meeting held on September 01, 2023 approved Appointment of Ms. Neha Kankariya as Company Secretary and Compliance Officer of theCompany with effect from, September 01, 2023. Ms. Neha Kankariya is a qualified Company Secretary having experience of more than 5 years in Listed Companies and having soundexposure in secretarial and legal matters. Resignation of Ms. Aakanksha as an Independent Director of the Company with effect from, September 01, 2023. Appointment of Mr. Suman Mallu as an Additional Director of the Company with effect from, September 01, 2023 in Independent category. Mr. Suman Mallu is a senior architect in Bosch Limited an automotive Industry. He is having a rich experience of more than 14 years in this field.
お知らせ • Sep 01Bandaram Pharma Packtech Limited Announces Resignation of Harish Sharma as Company Secretary and Compliance OfficerBandaram Pharma Packtech Limited announced that Mr. Harish Sharma has resigned from the post of Company Secretary and Compliance officer due to his personal reasons with effect from August 31, 2023 (close of Business hours).
お知らせ • Aug 05Bandaram Pharma Packtech Limited to Report Q1, 2024 Results on Aug 11, 2023Bandaram Pharma Packtech Limited announced that they will report Q1, 2024 results on Aug 11, 2023
New Risk • Aug 04New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 300% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.8x net interest cover). Shares are highly illiquid. High level of non-cash earnings (41% accrual ratio). Shareholders have been substantially diluted in the past year (300% increase in shares outstanding). Market cap is less than US$10m (₹335.6m market cap, or US$4.05m). Minor Risks Paying a dividend despite having no free cash flows. Revenue is less than US$5m (₹189m revenue, or US$2.3m).
Board Change • Jul 24Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 7 new directors. No experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Non-Executive Chairman Bhandaram Reddy is the most experienced director on the board, commencing their role in 2022. Additional Independent Director Aakanksha . was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Board Change • Jul 03Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 7 new directors. No experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Non-Executive Chairman Bhandaram Reddy is the most experienced director on the board, commencing their role in 2022. Additional Independent Director Aakanksha . was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • May 31Bandaram Pharma Packtech Limited Recommends DividendBandaram Pharma Packtech Limited recommended a dividend of INR 0.10 (10 paisa) per share subject to approval of members at the upcoming Annual General Meeting.
お知らせ • May 26Bandaram Pharma Packtech Limited to Report Q4, 2023 Results on May 30, 2023Bandaram Pharma Packtech Limited announced that they will report Q4, 2023 results on May 30, 2023
Board Change • May 08Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 7 new directors. No experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Non-Executive Chairman Bhandaram Reddy is the most experienced director on the board, commencing their role in 2022. Additional Independent Director Aakanksha . was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Board Change • Apr 10Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 7 new directors. No experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Non-Executive Chairman Bhandaram Reddy is the most experienced director on the board, commencing their role in 2022. Additional Independent Director Aakanksha . was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Board Change • Feb 27Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Additional Independent Director Aakanksha . was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Feb 08Bandaram Pharma Packtech Limited Announces Executive ChangesBandaram Pharma Packtech Limited announces Change in designation of Mr. B. Muniratnam Reddy from Managing Director to Non-Executive Chairman of the Company. Appointment of Mr. B. Deepak Reddy as Additional director and Managing Director (Executive Category) of the Company. Appointment of Ms. Aakanksha as additional director (Independent Category) of the Company.
お知らせ • Jan 25Bandaram Pharma Packtech Limited to Report Q3, 2023 Results on Feb 01, 2023Bandaram Pharma Packtech Limited announced that they will report Q3, 2023 results on Feb 01, 2023
Board Change • Nov 22Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Venkata Rajaram Chittuluru was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.